Evidence for dupilumab in teens with atopic dermatitis

Dupilumab is effective in easing symptoms in adolescents with moderate to severe atopic dermatitis, according to research published in JAMA Dermatology. A phase 3 randomised controlled trial compared 16 weeks of fortnightly (200 or 300 mg) or monthly (300 mg) dupilumab monotherapy with placebo in 250 adolescents, 12 to 18 year old. The study found ...

Already a member?

Login to keep reading.

© 2021 the limbic